Fisetin Targets Aging, Cancer, and Inflammation Through Multiple Pathways
A comprehensive review reveals fisetin's broad therapeutic potential spanning senescence, neurodegeneration, and cancer — with key bioavailability hurdles to overcome.
Summary
Fisetin, a flavonoid found in strawberries, apples, and onions, has emerged as a compelling multi-target compound with antioxidant, anti-inflammatory, anticancer, and neuroprotective properties. This 2026 review synthesizes its pharmacokinetics, molecular mechanisms, and biological activities, highlighting how fisetin modulates key signaling pathways, induces apoptosis in tumor cells, and shields neurons from oxidative damage. It also demonstrates hepatoprotective, antiviral, and gastroprotective effects. Despite its promise, fisetin faces significant clinical challenges: poor water solubility and low bioavailability limit its therapeutic delivery. Researchers are actively developing novel formulations to address these barriers. The review also flags genotoxicity concerns at high concentrations and outlines priorities for future clinical trials, positioning fisetin as a serious candidate for age-related and chronic disease treatment.
Detailed Summary
Fisetin is a naturally occurring flavonol abundant in common fruits and vegetables, yet it has attracted intense scientific interest for its remarkably broad pharmacological profile. As aging-related diseases and cancer continue to burden global health, identifying safe, multi-target compounds from dietary sources represents a high-priority research avenue. Fisetin sits at the intersection of several critical longevity-relevant mechanisms, making this comprehensive review particularly timely.
This paper is a narrative review synthesizing existing literature on fisetin's pharmacokinetics, biological activities, and molecular mechanisms. The authors draw on preclinical studies, mechanistic research, and data from ongoing clinical trials to construct an integrated picture of how fisetin exerts its effects across multiple organ systems and disease contexts.
Key findings confirm fisetin's potent antioxidant and anti-inflammatory actions, mediated through modulation of major cellular signaling pathways. It induces apoptosis and inhibits tumor proliferation in cancer models, while simultaneously offering neuroprotection against oxidative and inflammatory neurodegeneration. Additional benefits include hepatoprotective, antiviral, and gastroprotective activities, underscoring its systemic reach.
For longevity researchers, fisetin's senolytic properties — its ability to selectively clear senescent cells — are of particular interest, as cellular senescence is a central driver of aging. Its multi-pathway activity positions it as a candidate for addressing the complex, interconnected biology of aging rather than single-target interventions.
However, significant caveats temper enthusiasm. Fisetin's poor aqueous solubility and low oral bioavailability remain major translational obstacles. Genotoxicity signals at higher concentrations raise safety questions that must be resolved before widespread clinical use. The authors acknowledge that most evidence remains preclinical, and robust human trial data are still limited, making formulation innovation and rigorous clinical validation essential next steps.
Key Findings
- Fisetin modulates multiple signaling pathways to induce apoptosis and suppress tumor growth in cancer models.
- Strong antioxidant and anti-inflammatory activity protects neurons, liver, and gastrointestinal tissues from damage.
- Senolytic and neuroprotective properties make fisetin directly relevant to aging biology and neurodegeneration.
- Poor solubility and low bioavailability are primary barriers to clinical translation, driving novel formulation research.
- Genotoxicity observed at high concentrations signals the need for careful dose optimization in human trials.
Methodology
This is a comprehensive narrative review, not an original experimental study. The authors synthesized pharmacokinetic, mechanistic, and clinical trial data from existing published literature. No new experimental data were generated by the review authors.
Study Limitations
The review is based solely on an abstract, limiting access to the full scope of evidence evaluated and specific mechanistic details. As a narrative review, it may be subject to selection bias in the literature included. Human clinical trial data on fisetin remain sparse, and most mechanistic findings derive from in vitro or animal models with uncertain translatability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.